Skip to main content

CELULAS MIELOIDES Y PLASTICIDAD EPIGENETICA: MECANISMOS E IMPLICACIONES EN PROCESOS AUTOINMUNES E INFLAMATORIOS

SAF2017-88086-R

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos I+D+i Retos de Investigación
Call year 2017
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACIO INSTITUT D INVESTIGACIO BIOMEDICA DE BELLVITGE (IDIBELL)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 12
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Inflammatory cytokines shape a changing DNA methylome in monocytes mirroring disease activity in rheumatoid arthritis

  • Rodríguez-Ubreva, Javier
  • Calle-Fabregat, Carlos de la
  • Li, T.
  • Ciudad, Laura
  • Ballestar, M.L.
  • Català-Moll, Francesc
  • Morante-Palacios, O.
  • García-Gómez, Antonio
  • Celis, Raquel
  • Humby, F.
  • Nerviani, A.
  • Martín, J.
  • Pitzalis, C.
  • Cañete, Juan D.
  • Ballestar, Estéban
Objective: Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease that mainly targets joints. Monocytes and macrophages are critical in RA pathogenesis and contribute to inflammatory lesions. These extremely plastic cells respond to extracellular signals which cause epigenomic changes that define their pathogenic phenotype. Here, we interrogated how DNA methylation alterations in RA monocytes are determined by extracellular signals. Methods: High-throughput DNA methylation analyses of patients with RA and controls and in vitro cytokine stimulation were used to investigate the underlying mechanisms behind DNA methylation alterations in RA as well as their relationship with clinical parameters, including RA disease activity. Results: The DNA methylomes of peripheral blood monocytes displayed significant changes and increased variability in patients with RA with respect to healthy controls. Changes in the monocyte methylome correlate with DAS28, in which high-activity patients are divergent from healthy controls in contrast to remission patients whose methylome is virtually identical to healthy controls. Indeed, the notion of a changing monocyte methylome is supported after comparing the profiles of same individuals at different stages of activity. We show how these changes are mediated by an increase in disease activity-associated cytokines, such as tumour necrosis factor alpha and interferons, as they recapitulate the DNA methylation changes observed in patients in vitro. Conclusion: We demonstrate a direct link between RA disease activity and the monocyte methylome through the action of inflammation-associated cytokines. Finally, we have obtained a DNA methylation-based mathematical formula that predicts inflammation-mediated disease activity for RA and other chronic immune-mediated inflammatory diseases., We thank CERCA Programme/Generalitat de Catalunya for institutional support. EB was funded by the Spanish Ministry of Economy and Competitiveness (MINECO; grant numbers SAF2014-55942-R and SAF2017-88086-R). JDC was funded by FIS grant (PI17/00993) from Institute of Health Carlos III (ISCIII). JDC, JM and EB are supported by RETICS network grant from ISCIII (RIER, RD16/0012/0013), FEDER 'Una manera de hacer Europa'
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Epigenomics and transcriptomics of systemic sclerosis CD4+ T cells reveal long-range dysregulation of key inflammatory pathways mediated by disease-associated susceptibility loci

  • Li, Tianlu
  • Ortiz-Fernández, Lourdes
  • Andrés-León, Eduardo
  • Ciudad, Laura
  • Javierre, Biola M.
  • López-Isac, Elena
  • Guillén del Castillo, Alfredo
  • Simeón, Carmen P.
  • Ballestar, Estéban
  • Martín, Javier
© The Author(s). 2020., [Background]: Systemic sclerosis (SSc) is a genetically complex autoimmune disease mediated by the interplay between genetic and epigenetic factors in a multitude of immune cells, with CD4+ T lymphocytes as one of the principle drivers of pathogenesis., [Methods]: DNA samples exacted from CD4+ T cells of 48 SSc patients and 16 healthy controls were hybridized on MethylationEPIC BeadChip array. In parallel, gene expression was interrogated by hybridizing total RNA on Clariom™ S array. Downstream bioinformatics analyses were performed to identify correlating differentially methylated CpG positions (DMPs) and differentially expressed genes (DEGs), which were then confirmed utilizing previously published promoter capture Hi-C (PCHi-C) data., [Results]: We identified 9112 and 3929 DMPs and DEGs, respectively. These DMPs and DEGs are enriched in functional categories related to inflammation and T cell biology. Furthermore, correlation analysis identified 17,500 possible DMP-DEG interaction pairs within a window of 5 Mb, and utilizing PCHi-C data, we observed that 212 CD4+ T cell-specific pairs of DMP-DEG also formed part of three-dimensional promoter-enhancer networks, potentially involving CTCF. Finally, combining PCHi-C data with SSc GWAS data, we identified four important SSc-associated susceptibility loci, TNIP1 (rs3792783), GSDMB (rs9303277), IL12RB1 (rs2305743), and CSK (rs1378942), that could potentially interact with DMP-DEG pairs cg17239269-ANXA6, cg19458020-CCR7, cg10808810-JUND, and cg11062629-ULK3, respectively., [Conclusion]: Our study unveils a potential link between genetic, epigenetic, and transcriptional deregulation in CD4+ T cells of SSc patients, providing a novel integrated view of molecular components driving SSc pathogenesis., We thank CERCA Programme/Generalitat de Catalunya and the Josep Carreras Foundation for institutional support. E.B. was funded by the Ministry of Science and Innovation (MICINN; grant number SAF2017-88086-R). J.M. was funded by the Ministry of Science and Innovation (MICINN; grant number RT2018-101332-B-I00). J.M. and E.B. are supported by RETICS network grant from ISCIII (RIER, RD16/0012/0013), FEDER “Una manera de hacer Europa.”, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Targeting aberrant DNA methylation in mesenchymal stromal cells as a treatment for myeloma bone disease

  • García-Gómez, Antonio
  • Li, Tianlu
  • Rodríguez-Ubreva, Javier
  • Ciudad, Laura
  • Català-Moll, Francesc
  • Godoy-Tena, Gerard
  • Martín-Sánchez, Montserrat
  • San-Segundo, Laura
  • Muntión, Sandra
  • Morales, Xabier
  • Ortiz-de-Solorzano, Carlos
  • Oyarzabal, Julen
  • San José-Enériz, Edurne
  • Esteller, M.
  • Agirre, Xavier
  • Prósper, Felipe
  • Garayoa, Mercedes
  • Ballestar, Estéban
© The Author(s) 2021., Multiple myeloma (MM) progression and myeloma-associated bone disease (MBD) are highly dependent on bone marrow mesenchymal stromal cells (MSCs). MM-MSCs exhibit abnormal transcriptomes, suggesting the involvement of epigenetic mechanisms governing their tumor-promoting functions and prolonged osteoblast suppression. Here, we identify widespread DNA methylation alterations of bone marrow-isolated MSCs from distinct MM stages, particularly in Homeobox genes involved in osteogenic differentiation that associate with their aberrant expression. Moreover, these DNA methylation changes are recapitulated in vitro by exposing MSCs from healthy individuals to MM cells. Pharmacological targeting of DNMTs and G9a with dual inhibitor CM-272 reverts the expression of hypermethylated osteogenic regulators and promotes osteoblast differentiation of myeloma MSCs. Most importantly, CM-272 treatment prevents tumor-associated bone loss and reduces tumor burden in a murine myeloma model. Our results demonstrate that epigenetic aberrancies mediate the impairment of bone formation in MM, and its targeting by CM-272 is able to reverse MBD., We thank CERCA Program/Generalitat de Catalunya and the Josep Carreras Foundation for institutional support. E.B. was funded by the Spanish Ministry of Science and Innovation (grant numbers SAF2014-55942-R and SAF2017-88086-R), co-funded by FEDER funds/European Regional Development Fund (ERDF)—a way to build Europe, and a Senior Research Award from the Multiple Myeloma Research Foundation (MMRF). C.O.-d.-S. was funded by the Spanish Ministry of Science, Innovation and Universities, under grant RTI2018-094494-B-C22 (MCIU/AEI/FEDER, UE). M.G. received financial support from the Spanish FIS-ISCIII (PI15/02156 and PI19/01384) and FEDER. A.G.G is funded by a postdoctoral contract of the Asociación Española Contra el Cáncer (AECC). F.P. was funded by grants from Instituto de Salud Carlos III (ISCIII), PI17/00701 and PI19/01352, TRASCAN (EPICA and Immunocell), Fundació La Marató de TV3, the Accelerator award CRUK/AIRC/AECC joint funder-partnership, CIBERONC (CB16/12/00489) and co-financed with FEDER funds and Fundación Ramón Areces (PREMAMM).
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Inflammatory cytokines and organ dysfunction associate with the aberrant DNA methylome of monocytes in sepsis

  • Lorente-Sorolla, Clara|||0000-0003-0404-9453
  • Garcia-Gomez, Antonio
  • Català-Moll, Francesc|||0000-0002-2354-8648
  • Toledano, Víctor
  • Ciudad, Laura|||0000-0002-5219-6792
  • Avendaño-Ortiz, José
  • Maroun-Eid, Charbel
  • Martín-Quirós, Alejandro
  • Martínez Gallo, Mónica|||0000-0002-7340-2161
  • Ruiz-Sanmartín, Adolfo|||0000-0001-5587-5419
  • del Campo, Álvaro García
  • Ferrer, Ricard|||0000-0002-4859-4747
  • Ruiz-Rodriguez, Juan Carlos|||0000-0001-7392-8617
  • Álvarez-Errico, Damiana|||0000-0002-7921-5164
  • Ballestar, Esteban|||0000-0002-1400-2440
Sepsis, a life-threatening organ dysfunction caused by a dysregulated systemic immune response to infection, associates with reduced responsiveness to subsequent infections. How such tolerance is acquired is not well understood but is known to involve epigenetic and transcriptional dysregulation. Bead arrays were used to compare global DNA methylation changes in patients with sepsis, non-infectious systemic inflammatory response syndrome, and healthy controls. Bioinformatic analyses were performed to dissect functional reprogramming and signaling pathways related to the acquisition of these specific DNA methylation alterations. Finally, in vitro experiments using human monocytes were performed to test the induction of similar DNA methylation reprogramming. Here, we focused on DNA methylation changes associated with sepsis, given their potential role in stabilizing altered phenotypes. Tolerized monocytes from patients with sepsis display changes in their DNA methylomes with respect to those from healthy controls, affecting critical monocyte-related genes. DNA methylation profiles correlate with IL-10 and IL-6 levels, significantly increased in monocytes in sepsis, as well as with the Sequential Organ Failure Assessment score; the observed changes associate with TFs and pathways downstream to toll-like receptors and inflammatory cytokines. In fact, in vitro stimulation of toll-like receptors in monocytes results in similar gains and losses of methylation together with the acquisition of tolerance. We have identified a DNA methylation signature associated with sepsis that is downstream to the response of monocytes to inflammatory signals associated with the acquisition of a tolerized phenotype and organic dysfunction.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

SIRT1/2 orchestrate acquisition of DNA methylation and loss of histone H3 activating marks to prevent premature activation of inflammatory genes in macrophages

  • Li, Tianlu|||0000-0001-7152-4870
  • Garcia-Gomez, Antonio
  • Morante-Palacios, Octavio|||0000-0002-6435-2756
  • Ciudad, Laura|||0000-0002-5219-6792
  • Özkaramehmet, S.
  • Van Dijck, E.
  • Rodríguez-Ubreva, Javier|||0000-0003-4707-4536
  • Vaquero, Alejandro|||0000-0002-8735-4156
  • Ballestar, Esteban|||0000-0002-1400-2440
Sirtuins 1 and 2 (SIRT1/2) are two NAD-dependent deacetylases with major roles in inflammation. In addition to deacetylating histones and other proteins, SIRT1/2-mediated regulation is coupled with other epigenetic enzymes. Here, we investigate the links between SIRT1/2 activity and DNA methylation in macrophage differentiation due to their relevance in myeloid cells. SIRT1/2 display drastic upregulation during macrophage differentiation and their inhibition impacts the expression of many inflammation-related genes. In this context, SIRT1/2 inhibition abrogates DNA methylation gains, but does not affect demethylation. Inhibition of hypermethylation occurs at many inflammatory loci, which results in more drastic upregulation of their expression upon macrophage polarization following bacterial lipopolysaccharide (LPS) challenge. SIRT1/2-mediated gains of methylation concur with decreases in activating histone marks, and their inhibition revert these histone marks to resemble an open chromatin. Remarkably, specific inhibition of DNA methyltransferases is sufficient to upregulate inflammatory genes that are maintained in a silent state by SIRT1/2. Both SIRT1 and SIRT2 directly interact with DNMT3B, and their binding to proinflammatory genes is lost upon exposure to LPS or through pharmacological inhibition of their activity. In all, we describe a novel role for SIRT1/2 to restrict premature activation of proinflammatory genes.
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

Understanding the relevance of DNA methylation changes in immune differentiation and disease

  • de la Calle-Fabregat, Carlos|||0000-0002-3026-3069
  • Morante-Palacios, Octavio|||0000-0002-6435-2756
  • Ballestar, Esteban|||0000-0002-1400-2440
Immune cells are one of the most complex and diverse systems in the human organism. Such diversity implies an intricate network of different cell types and interactions that are dependently interconnected. The processes by which different cell types differentiate from progenitors, mature, and finally exert their function requires an orchestrated succession of molecular processes that determine cell phenotype and function. The acquisition of these phenotypes is highly dependent on the establishment of unique epigenetic profiles that confer identity and function on the various types of effector cells. These epigenetic mechanisms integrate microenvironmental cues into the genome to establish specific transcriptional programs. Epigenetic modifications bridge environment and genome regulation and play a role in human diseases by their ability to modulate physiological programs through external stimuli. DNA methylation is one of the most ubiquitous, stable, and widely studied epigenetic modifications. Recent technological advances have facilitated the generation of a vast amount of genome-wide DNA methylation data, providing profound insights into the roles of DNA methylation in health and disease. This review considers the relevance of DNA methylation to immune system cellular development and function, as well as the participation of DNA methylation defects in immune-mediated pathologies, illustrated by selected paradigmatic diseases.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Epigenomics and transcriptomics of systemic sclerosis CD4+ T cells reveal long-range dysregulation of key inflammatory pathways mediated by disease-associated susceptibility loci

  • Li, Tianlu|||0000-0001-7152-4870
  • Ortiz-Fernández, Lourdes|||0000-0002-0247-4280
  • Andrés-León, Eduardo|||0000-0002-0621-9914
  • Ciudad, Laura|||0000-0002-5219-6792
  • Javierre, B. M.|||0000-0002-8682-6748
  • López-Isac, E.
  • Guillén-Del-Castillo, A.
  • Simeón-Aznar, C. P.
  • Ballestar, Esteban|||0000-0002-1400-2440
  • Martín, Javier|||0000-0002-2202-0622
Background: Systemic sclerosis (SSc) is a genetically complex autoimmune disease mediated by the interplay between genetic and epigenetic factors in a multitude of immune cells, with CD4+ T lymphocytes as one of the principle drivers of pathogenesis. Methods: DNA samples exacted from CD4+ T cells of 48 SSc patients and 16 healthy controls were hybridized on MethylationEPIC BeadChip array. In parallel, gene expression was interrogated by hybridizing total RNA on Clariom™ S array. Downstream bioinformatics analyses were performed to identify correlating differentially methylated CpG positions (DMPs) and differentially expressed genes (DEGs), which were then confirmed utilizing previously published promoter capture Hi-C (PCHi-C) data. Results: We identified 9112 and 3929 DMPs and DEGs, respectively. These DMPs and DEGs are enriched in functional categories related to inflammation and T cell biology. Furthermore, correlation analysis identified 17,500 possible DMP-DEG interaction pairs within a window of 5 Mb, and utilizing PCHi-C data, we observed that 212 CD4+ T cell-specific pairs of DMP-DEG also formed part of three-dimensional promoter-enhancer networks, potentially involving CTCF. Finally, combining PCHi-C data with SSc GWAS data, we identified four important SSc-associated susceptibility loci, TNIP1 (rs3792783), GSDMB (rs9303277), IL12RB1 (rs2305743), and CSK (rs1378942), that could potentially interact with DMP-DEG pairs cg17239269-ANXA6, cg19458020-CCR7, cg10808810-JUND, and cg11062629-ULK3, respectively. Conclusion: Our study unveils a potential link between genetic, epigenetic, and transcriptional deregulation in CD4+ T cells of SSc patients, providing a novel integrated view of molecular components driving SSc pathogenesis.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Activation-induced deaminase is critical for the establishment of DNA methylation patterns prior to the germinal center reaction

  • Català-Moll, Francesc|||0000-0002-2354-8648
  • Ferreté-Bonastre, Anna G.|||0000-0003-3327-6129
  • Li, Tianlu|||0000-0001-7152-4870
  • Weichenhan, Dieter
  • Lutsik, Pavlo
  • Ciudad, Laura|||0000-0002-5219-6792
  • Álvarez-Prado, Ángel F.
  • Rodríguez-Ubreva, Javier|||0000-0003-4707-4536
  • Klemann, Christian
  • Speckmann, Carsten
  • Vilas-Zornoza, Amaya
  • Abolhassani, Hassan|||0000-0002-4838-0407
  • Martínez Gallo, Mónica|||0000-0002-7340-2161
  • Dieli-Crimi, Romina|||0000-0003-3413-5133
  • Rivière, Jacques G.|||0000-0003-1055-2063
  • Martín Nalda, Andrea|||0000-0002-1715-153X
  • Colobrán Oriol, Roger|||0000-0002-5964-536X
  • Soler Palacín, Pere|||0000-0002-0346-5570
  • Kracker, Sven
  • Hammarström, Lennart|||0000-0002-8635-9609
  • Prosper, Felipe|||0000-0001-6115-8790
  • Durandy, Anne
  • Grimbacher, Bodo
  • Plass, Christoph|||0000-0003-2554-3952
  • Ballestar, Esteban|||0000-0002-1400-2440
Activation-induced deaminase (AID) initiates antibody diversification in germinal center B cells by deaminating cytosines, leading to somatic hypermutation and class-switch recombination. Loss-of-function mutations in AID lead to hyper-IgM syndrome type 2 (HIGM2), a rare human primary antibody deficiency. AID-mediated deamination has been proposed as leading to active demethylation of 5-methycytosines in the DNA, although evidence both supports and casts doubt on such a role. In this study, using whole-genome bisulfite sequencing of HIGM2 B cells, we investigated direct AID involvement in active DNA demethylation. HIGM2 naïve and memory B cells both display widespread DNA methylation alterations, of which ∼25% are attributable to active DNA demethylation. For genes that undergo active demethylation that is impaired in HIGM2 individuals, our analysis indicates that AID is not directly involved. We demonstrate that the widespread alterations in the DNA methylation and expression profiles of HIGM2 naïve B cells result from premature overstimulation of the B-cell receptor prior to the germinal center reaction. Our data support a role for AID in B cell central tolerance in preventing the expansion of autoreactive cell clones, affecting the correct establishment of DNA methylation patterns.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Coordinated glucocorticoid receptor and MAFB action induces tolerogenesis and epigenome remodeling in dendritic cells

  • Morante-Palacios, Octavio|||0000-0002-6435-2756
  • Ciudad, Laura|||0000-0002-5219-6792
  • Micheroli, Raphael|||0000-0002-8918-7304
  • de la Calle-Fabregat, Carlos|||0000-0002-3026-3069
  • Li, Tianlu|||0000-0001-7152-4870
  • Barbisan, Gisela
  • Houtman, Miranda
  • Edalat, Sam G.
  • Frank-Bertoncelj, Mojca|||0000-0002-7257-2468
  • Ospelt, Caroline|||0000-0002-9151-4650
  • Ballestar, Esteban|||0000-0002-1400-2440
Glucocorticoids (GCs) exert potent anti-inflammatory effects in immune cells through the glucocorticoid receptor (GR). Dendritic cells (DCs), central actors for coordinating immune responses, acquire tolerogenic properties in response to GCs. Tolerogenic DCs (tolDCs) have emerged as a potential treatment for various inflammatory diseases. To date, the underlying cell type-specific regulatory mechanisms orchestrating GC-mediated acquisition of immunosuppressive properties remain poorly understood. In this study, we investigated the transcriptomic and epigenomic remodeling associated with differentiation to DCs in the presence of GCs. Our analysis demonstrates a major role of MAFB in this process, in synergy with GR. GR and MAFB both interact with methylcytosine dioxygenase TET2 and bind to genomic loci that undergo specific demethylation in tolDCs. We also show that the role of MAFB is more extensive, binding to thousands of genomic loci in tolDCs. Finally, MAFB knockdown erases the tolerogenic properties of tolDCs and reverts the specific DNA demethylation and gene upregulation. The preeminent role of MAFB is also demonstrated in vivo for myeloid cells from synovium in rheumatoid arthritis following GC treatment. Our results imply that, once directly activated by GR, MAFB plays a critical role in orchestrating the epigenomic and transcriptomic remodeling that define the tolerogenic phenotype.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

JAK2-STAT Epigenetically Regulates Tolerized Genes in Monocytes in the First Encounter With Gram-Negative Bacterial Endotoxins in Sepsis

  • Morante-Palacios, Octavio|||0000-0002-6435-2756
  • Lorente-Sorolla, Clara|||0000-0003-0404-9453
  • Ciudad, Laura|||0000-0002-5219-6792
  • Calafell-Segura, Josep|||0000-0002-0173-8221
  • Garcia-Gomez, Antonio
  • Català-Moll, Francesc|||0000-0002-2354-8648
  • Ruiz-Sanmartín, Adolfo|||0000-0001-5587-5419
  • Martínez Gallo, Mónica|||0000-0002-7340-2161
  • Ferrer, Ricard|||0000-0002-4859-4747
  • Ruiz-Rodriguez, Juan Carlos|||0000-0001-7392-8617
  • Álvarez-Errico, Damiana|||0000-0002-7921-5164
  • Ballestar, Esteban|||0000-0002-1400-2440
Microbial challenges, such as widespread bacterial infection in sepsis, induce endotoxin tolerance, a state of hyporesponsiveness to subsequent infections. The participation of DNA methylation in this process is poorly known. In this study, we perform integrated analysis of DNA methylation and transcriptional changes following in vitro exposure to gram-negative bacterial lipopolysaccharide, together with analysis of ex vivo monocytes from septic patients. We identify TET2-mediated demethylation and transcriptional activation of inflammation-related genes that is specific to toll-like receptor stimulation. Changes also involve phosphorylation of STAT1, STAT3 and STAT5, elements of the JAK2 pathway. JAK2 pathway inhibition impairs the activation of tolerized genes on the first encounter with lipopolysaccharide. We then confirm the implication of the JAK2-STAT pathway in the aberrant DNA methylome of patients with sepsis caused by gram-negative bacteria. Finally, JAK2 inhibition in monocytes partially recapitulates the expression changes produced in the immunosuppressive cellular state acquired by monocytes from gram-negative sepsis, as described by single cell-RNA-sequencing. Our study evidences both the crucial role the JAK2-STAT pathway in epigenetic regulation and initial response of the tolerized genes to gram-negative bacterial endotoxins and provides a pharmacological target to prevent exacerbated responses.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Targeting aberrant DNA methylation in mesenchymal stromal cells as a treatment for myeloma bone disease

  • García Gómez, Antonio
  • Li, Tianlu|||0000-0001-7152-4870
  • de la Calle-Fabregat, Carlos|||0000-0002-3026-3069
  • Rodríguez-Ubreva, Javier|||0000-0003-4707-4536
  • Ciudad, Laura|||0000-0002-5219-6792
  • Català-Moll, Francesc|||0000-0002-2354-8648
  • Godoy-Tena, Gerard|||0000-0003-3832-5794
  • Martín Sánchez, Montserrat
  • San Segundo, Laura|||0000-0003-2391-5935
  • Muntión, Sandra|||0000-0001-7164-0767
  • Morales Urteaga, Xabier|||0000-0003-0303-9958
  • Ortiz de Solórzano, Carlos|||0000-0001-8720-0205
  • Oyarzabal, Julen|||0000-0003-1941-7255
  • San José Enériz, Edurne|||0000-0001-5786-5273
  • Esteller, M|||0000-0003-4490-6093
  • Agirre, Xabier|||0000-0002-6558-9560
  • Prosper, Felipe|||0000-0001-6115-8790
  • Garayoa, Mercedes|||0000-0003-2194-2841
  • Ballestar, Esteban|||0000-0002-1400-2440
Multiple myeloma (MM) progression and myeloma-associated bone disease (MBD) are highly dependent on bone marrow mesenchymal stromal cells (MSCs). MM-MSCs exhibit abnormal transcriptomes, suggesting the involvement of epigenetic mechanisms governing their tumor-promoting functions and prolonged osteoblast suppression. Here, we identify widespread DNA methylation alterations of bone marrow-isolated MSCs from distinct MM stages, particularly in Homeobox genes involved in osteogenic differentiation that associate with their aberrant expression. Moreover, these DNA methylation changes are recapitulated in vitro by exposing MSCs from healthy individuals to MM cells. Pharmacological targeting of DNMTs and G9a with dual inhibitor CM-272 reverts the expression of hypermethylated osteogenic regulators and promotes osteoblast differentiation of myeloma MSCs. Most importantly, CM-272 treatment prevents tumor-associated bone loss and reduces tumor burden in a murine myeloma model. Our results demonstrate that epigenetic aberrancies mediate the impairment of bone formation in MM, and its targeting by CM-272 is able to reverse MBD.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The synovial and blood monocyte DNA methylomes mirror prognosis, evolution, and treatment in early arthritis

  • de la Calle-Fabregat, Carlos|||0000-0002-3026-3069
  • Rodríguez-Ubreva, Javier|||0000-0003-4707-4536
  • Ciudad, Laura|||0000-0002-5219-6792
  • Ramírez, Julio
  • Celis, Raquel|||0000-0002-5096-4532
  • Azuaga, Ana Belén
  • Cuervo, Andrea
  • Graell, Eduard|||0000-0002-4210-2721
  • Pérez-García, Carolina|||0000-0002-6695-6406
  • Diaz-Torne, Cesar|||0000-0001-6275-7699
  • Salvador, Georgina
  • Gómez-Puerta, Jose A.|||0000-0001-8177-702X
  • Haro, Isabel|||0000-0001-8677-2340
  • Sanmartí, Raimon|||0000-0002-8864-3806
  • Cañete, Juan D.|||0000-0003-2606-0573
  • Ballestar, Esteban|||0000-0002-1400-2440
Identifying predictive biomarkers at early stages of inflammatory arthritis is crucial for starting appropriate therapies to avoid poor outcomes. Monocytes (MOs) and macrophages, largely associated with arthritis, are contributors and sensors of inflammation through epigenetic modifications. In this study, we investigated associations between clinical features and DNA methylation in blood and synovial fluid (SF) MOs in a prospective cohort of patients with early inflammatory arthritis. DNA methylation profiles of undifferentiated arthritis (UA) blood MOs exhibited marked alterations in comparison with those from healthy donors. We identified additional differences both in blood and SF MOs after comparing patients with UA grouped by their future outcomes, i.e., good versus poor. Patient profiles in subsequent visits revealed a reversion toward a healthy level in both groups, those requiring disease-modifying antirheumatic drugs and those who remitted spontaneously. Changes in disease activity between visits also affected DNA methylation, which was partially concomitant in the SF of UA and in blood MOs of patients with rheumatoid arthritis. Epigenetic similarities between arthritis types allow a common prediction of disease activity. Our results constitute a resource of DNA methylation-based biomarkers of poor prognosis, disease activity, and treatment efficacy for the personalized clinical management of early inflammatory arthritis.